CereScan to Present During World Entrepreneur Forum

World Entrepreneur Forum

Steve Warnecke, President of CereHealth Corp., parent company of CereScan®, will be presenting the company’s brain data analytics platform, CereMetrix® at the World Entrepreneur Forum in Vancouver, BC on July 14, 2017.

The conference, hosted by Venture Development Canucks in partnership with UBC, is focused on “Finding the Next Edison” through its invitation to fast growth innovative companies with cutting edge technologies, who will be presenting to international venture capitalists and business strategists.

CereMetrix® is a brain-focused medical analytics platform that may accelerate the accurate and effective diagnosis of complex brain-related disorders to improve treatment and outcomes for patients.

“The opportunity to present our story and CereMetrix’s evolution at the World Entrepreneur Forum is an important step in gaining international exposure and access to global markets through an audience of recognized business leaders and strategists,” expressed Mr. Warnecke.  “I’m honored to have been invited, and excited to explore business development opportunities with this esteemed group of Canadian and multi-national trailblazers in business and innovation.”

About CereScan

CereScan® combines state-of-the-art brain imaging technologies with a patient-centered model of care to provide the highest level of neuro-diagnostics available. CereScan® utilizes state-of-the-art gamma camera technology, new generation imaging software and a proprietary process to produce comprehensive medical reports including voxel level images of brain function and physiology. Our functional brain imaging technologies are the most sophisticated in the world today. Additional information about the company is available at https://cerescan.com.

For more information on CereMetrix® visit http://ceremetrix.io/ , or contact us through hello@ceremetrix.io or by calling (855)-838-2241.

CereScan® and CereMetrix® are registered trademarks of CereHealth Corp.

What the Amazon acquisition of Whole Foods tells us about medical technology

Medical Icons

I’m a big believer in learning business lessons wherever and whenever I can. I may hear a speaker suggest something or read a column that gets me thinking of how to apply that idea or concept to our business. Even when the issue is clearly ions away from our primary interests, I can almost always find a parable or analogy that brings the learning back to what’s in front of me.

Even so, many might say it’s too far a stretch for me to see a lesson applicable to the medical device industry, or even the broader healthcare sector, in the Amazon acquisition of Whole Foods last month. Let me explain why this transaction actually teaches a critical lesson for all of us concerned with bringing innovation to the world’s doctors, nurses and, most importantly, patients.

Beyond the almost cliché role of disruptor, which it has been perfecting since the days the company started changing how and where books are sold, Amazon is also showing that it can cross channels to make them more efficient for the ultimate consumer. What Jeff Bezos did by forcing publishers, authors, and everybody else along the book supply chain to cut their costs, he is now attempting to do with groceries.  The outcome for food manufacturers may be as existensially challenging as it was for book sellers.

Apply this lesson of disintermediation and productivity enhancement to the healthcare industry with technologies like Artificial Intelligence (AI) and you have the colliding of disruptors that simultaneously knock existing companies off of their current models.  This has the immediate impact of propelling the patient or end user to the front of the line when it comes to improved diagnosis and ultimately improved outcomes.  With AI and advanced machine learning algorithms, improved healthcare will result from the ability to instanteously reveal intelligent information from totally different data sets.  For example, the marrying of detailed, pattern matching information from Neurology, Radiology and Psychiatry may very well improve optimal clinical and medical solutions for patients.

The AI market for healthcare applications, which is expected to double every two years for the next decade, should also result in reduced treatment costs and the elimination of unnecessary hospital procedures. Soon enough, chronic conditions like cancer, Alzheimers disease, and chronic traumatic brain injuries will be diagnosed in minutes.  This will be accomplished by using AI applications systems that identify and compare all available characteristics in the patients medical history, testing, scanning, blood markers and other available information.  If that’s not an industry disruptor, I don’t know what one is.

The primary question to companies facing this onslaught, like those now assessing the combination of Amazon and Whole Foods, is what can I do to keep up?  A recent column on the Amazon acquisition of Whole Foods at Forbes.com captures this perfectly, particularly a few sentences toward the end; “Innovators have already been using Big Data, AI and ML. And if you’re hearing about them now, it might be too late.

John A. Kelley, Jr., is Chairman and CEO of CereScan, a functional brain diagnostics company headquartered in Denver.

 

Medical innovation and progress don’t have to stop under tight federal budgets

 

Budget Planning

There has been a lot of discussion about Pres. Trump’s first budget submission, particularly in healthcare channels, leading to more questions than answers. Will Medicaid really be cut by billions of dollars? Are certain research programs and pharmaceutical regulations destined for the scrap heap? Will the CDC and NIH have their budgets slashed? The list goes on.

There is an excellent article in The Atlantic that provides insight into the impact of the budget on healthcare, much of which is negative for many of us in the sector. Instead of reviewing the downside, I want to focus on the opportunities and trend away from simply piling on regarding the issue the proposed budget cuts will create. These opportunities arise from having to make difficult choices based on fewer resources available to address specific challenges. It may sound counter-intuitive, but those choices over diminished fund allocations can actually lead to dramatic advancement of research in health and diagnostics.

How?

The traditional path to innovation in healthcare is for researchers to receive money from the government and other sources, develop a solution to a specific medical challenge, seek approval from governmental bodies and then endeavor to commercialize the pharmaceutical device or process. The creative way to bring innovations to market is to secure private sector funding, then compliant testing and ultimately commercialization. This new approach is obtainable because technology has advanced to the point where data can be shared across boundaries.  This sharing accelerates innovations that are works of collaboration between many different companies and organizations. This is exactly what investors want in a business model, and has been successfully used in many industries.

The healthcare sector has operated with a margin of error that can now be reduced by deploying the latest in information systems technologies.  These new advancements enhance an organization’s ability to move new products and procedures through to commercialization more effectively. Data analytics is a great example of technology that has consistently been advancing to the point where stakeholders can fully coordinate intelligent information to better understand the needs of each patient. These stakeholders can realistically implement artificial intelligence, machine learning and other analytic technologies to fill the void and continue to be proactive in helping drive that more comprehensive view of the patient.

This research to personalize the care process is more important than ever because any potential cuts at the federal level will require more efficient use of treatment resources. If doctors can combine data sources at the point of care delivery to more precisely and immediately diagnose and treat illnesses, they can potentially save billions of dollars a year for the healthcare system.

As Harvard Business School’s Clayton Christiansen has said, machine learning is going to happen in a big way in the healthcare provider channel whether the channel likes it or not. The change will happen either through disruptive innovation, a process by which a product or service takes root initially in simple applications at the bottom of a market and then relentlessly moves up market, or through a more gradual evolution that is spurred on by existing stakeholders responding to the changing marketplace. Given those potential budget cuts, stakeholders should plan for disruptions but innovation that will be positive for the healthcare industry.

John A. Kelley, Jr., is Chairman and CEO of CereScan, a functional brain diagnostics company headquartered in Denver.

CereScan’s Latest Patent for its Neuroimaging Database Now Covers All Brain Activity Measurement Methods

CereMetrix CereScan Patent

In response to an application filed with the United States Patent and Trademark Office, CereScan® has broadened the parameters on its automated diagnostic assistance and intelligent support system, CereMetrix®, which uses quantitative measurements to assist in the diagnosis and study of complex brain disorders.  Through award of a second patent, the company may now claim exclusive use of its neuroimaging database systems and methods in the measurement of all types of brain activity.  The patent expands CereScan’s intellectual property and use of its wholly owned data warehouse, known to be the most comprehensive store of functional brain imaging data, associated patient demographic, clinical information and biomarkers worldwide.

“CereScan® is transforming the future of advanced brain diagnostics and use of intelligent learning to benefit those suffering from and studying complex brain disorders,” said John Kelley, CEO and Chairman of CereScan®. “The expansion of our patent allows us to apply key learnings to all manners of brain measurement, and vastly expands the potential for advancements in brain science using technology.”

Read More: CereScan Taps The Ohio State University to Advance Functional Brain Diagnostic System

Headquartered in Denver, CereScan® uses its patented methods, combining patient-clinical information, functional brain imaging and advanced processing software to help medical professionals identify abnormal brain physiology and activity using correlative data and pattern matching contained within its extensive data warehouse.  Through the application of technology to traditional medical practice, CereScan® has assumed a leadership role in advancing precision brain diagnostics and science.  Its first patent was awarded in September of 2014, and allowed for exclusive utilization of it systems and methods under more limited claims.

CereScan® is uniquely positioned to capitalize on a planned release of CereMetrix®, its MAaS (Medical Analytics as a Service) platform in 2017.  Its patented technology is considered by industry insiders to be a positive disruptor in the field of diagnostic radiology.  CereScan’s MAaS product suite incorporated into its CereMetrix® offering is being labeled as revolutionary, based on early feedback from Radiologists, Neurologists, and Psychiatrists who have had a chance to experiment with early release versions.

About CereScan® 
CereScan® combines state-of-the-art brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides unbiased evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.

About CereMetrix®

CereMetrix® is an advanced healthcare analytics ecosystem that provides radiologists, practitioners and researchers with precise data about their patient’s brain health. Each new patient’s data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms. The unique brain diagnostic system and ever-expanding data warehouse includes over 7,000 scan encounters, including patients’ medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans, among other data points. Each scan is composed of over 262,000 data points that measure activity levels in up to 160 brain regions derived from comparisons to normative data.